Jarrod Marto, Ph.D., is a Professor at the University of Virginia in the Department of Biochemistry & Molecular Genetics, School of Medicine, and the Department of Chemistry, College of Arts & Sciences. Dr. Marto is internationally recognized for his expertise in the development and use of state-of-the-art mass spectrometry and other bioanalytical techniques to understand how genomic alterations as well as the activity of chemical probes or clinical drugs manifest at the level of individual targets, signaling pathways, or other compartments throughout the functional proteome. From 2004 to 2025 Dr. Marto served on the faculty of the Dana-Farber Cancer Institute and Harvard Medical School. In addition to his independent lab at the Dana-Farber, Dr. Marto also directed the Blais Proteomics Center and, along with Entact co-founder Dr. Sara Buhrlage, launched the Center for Emergent Drug Targets. His longstanding collaboration with Dr. Buhrlage also fostered development of a dedicated platform to accelerate the design and characterization of new chemical probes targeting deubiquitylase (DUB) family enzymes.

Dr. Marto has authored more than 200 peer-reviewed scientific papers across the fields of bioanalytical chemistry, scientific instrumentation, mass-informatics, chemical biology and cancer cell signaling. In addition, he has served on advisory boards for commercial and academic/non-profit research organizations. Dr. Marto holds multiple patents spanning analytical science, advanced instrumentation, and cancer therapeutics. Dr. Marto earned his Ph.D. in analytical chemistry with Alan Marshall at The Ohio State University and went on to postdoctoral studies with Don Hunt at the University of Virginia.